Literature DB >> 22083391

Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders.

Thomas C Baghai1, Pierre Blier, David S Baldwin, Michael Bauer, Guy M Goodwin, Kostas N Fountoulakis, Siegfried Kasper, Brian E Leonard, Ulrik F Malt, Dan J Stein, Marcio Versiani, Hans-Jürgen Möller.   

Abstract

Current gold standard in the treatment of depression includes pharmacotherapeutic and psychotherapeutic strategies together with social support. Due to the actually discussed controversies concerning the differential efficacy of antidepressants, a contribution to a comprehensive clarification seems to be necessary to avert further deterioration and uncertainty from patients, relatives, and their treating psychiatrists and general practitioners. Both efficacy and clinical effectiveness of antidepressants in the treatment of depressive disorders can be confirmed. Clinically meaningful antidepressant treatment effects were confirmed in different types of studies. Methodological issues of randomized controlled studies, meta-analyses, and effectiveness studies will be discussed. Furthermore, actual data about the differential efficacy and effectiveness of antidepressants with distinct pharmacodynamic properties and about outcome differences in studies using antidepressants and/or psychotherapy are discussed. This is followed by a clinically oriented depiction-the differential clinical effectiveness of different pharmacodynamic modes of action of antidepressants in different subtypes of depressive disorders. It can be summarized that the spectrum of different antidepressant treatments has broadened during the last decades. The efficacy and clinical effectiveness of antidepressants is statistically significant and clinically relevant and proven repeatedly. For further optimizing antidepressant treatment plans, clearly structured treatment algorithms and the implementation of psychotherapy seem to be useful. A modern individualized antidepressant treatment in most cases is a well-tolerated and efficacious tool to minimize the negative impact of the otherwise devastating and life-threatening outcome of depressive disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22083391     DOI: 10.1007/s00406-011-0274-7

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  119 in total

Review 1.  Efficacy and mechanisms of action of lithium augmentation in refractory major depression.

Authors:  Tom Bschor; Michael Bauer
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

2.  The psychological treatment of depression. Evidence for the efficacy of psychotherapy alone, in comparison with, and in combination with pharmacotherapy.

Authors:  M M Weissman
Journal:  Arch Gen Psychiatry       Date:  1979-10

3.  Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression.

Authors:  M Bauer; T Bschor; D Kunz; A Berghöfer; A Ströhle; B Müller-Oerlinghausen
Journal:  Am J Psychiatry       Date:  2000-09       Impact factor: 18.112

Review 4.  Antidepressant drug effects and depression severity: a patient-level meta-analysis.

Authors:  Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett
Journal:  JAMA       Date:  2010-01-06       Impact factor: 56.272

5.  Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.

Authors:  Andrew J Cutler; Stuart A Montgomery; David Feifel; Arthur Lazarus; Mikael Aström; Martin Brecher
Journal:  J Clin Psychiatry       Date:  2009-04-07       Impact factor: 4.384

6.  Outcomes of 1014 naturalistically treated inpatients with major depressive episode.

Authors:  Florian Seemüller; Michael Riedel; Michael Obermeier; Michael Bauer; Mazda Adli; Klaus Kronmüller; Florian Holsboer; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Joachim Zeiler; Wolfgang Gaebel; Eva Dichgans; Roland Bottländer; Richard Musil; Hans-Jürgen Möller
Journal:  Eur Neuropsychopharmacol       Date:  2010-01-22       Impact factor: 4.600

Review 7.  [Core symptoms of depression. Effectiveness of antidepressant therapy].

Authors:  J Damm; D Eser; C Schüle; H-J Möller; R Rupprecht; T C Baghai
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

Review 8.  Combined pharmacotherapy and psychological treatment for depression: a systematic review.

Authors:  Sandro Pampallona; Paola Bollini; Giuseppe Tibaldi; Bruce Kupelnick; Carmine Munizza
Journal:  Arch Gen Psychiatry       Date:  2004-07

Review 9.  Antidepressants versus placebo for depression in primary care.

Authors:  Bruce Arroll; C Raina Elley; Tana Fishman; Felicity A Goodyear-Smith; Tim Kenealy; Grant Blashki; Ngaire Kerse; Stephen Macgillivray
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.

Authors:  R Aronson; H J Offman; R T Joffe; C D Naylor
Journal:  Arch Gen Psychiatry       Date:  1996-09
View more
  7 in total

1.  Emotional status: diagnosis and treatment for severe psychiatric disorders.

Authors:  P Falkai; H-J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-02       Impact factor: 5.270

2.  Population impact of depression on functional disability in elderly: results from "São Paulo Ageing & Health Study" (SPAH).

Authors:  Simone Almeida da Silva; Marcia Scazufca; Paulo R Menezes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-08-08       Impact factor: 5.270

3.  Depression and anxiety in Swedish primary health care: prevalence, incidence, and risk factors.

Authors:  Nadja Lejtzén; Jan Sundquist; Kristina Sundquist; Xinjun Li
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-05       Impact factor: 5.270

4.  On the application of light therapy in German-speaking countries.

Authors:  Reinhard Fischer; Siegfried Kasper; Edda Pjrek; Dietmar Winkler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-01-07       Impact factor: 5.270

5.  A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities.

Authors:  Johanna Michl; Christian Scharinger; Miriam Zauner; Siegfried Kasper; Michael Freissmuth; Harald H Sitte; Gerhard F Ecker; Lukas Pezawas
Journal:  Eur Neuropsychopharmacol       Date:  2014-07-03       Impact factor: 4.600

6.  Differences in Cerebral Distribution between Imipramine and Paroxetine via Membrane Transporters at the Rat Blood-Brain Barrier.

Authors:  Shin-Ichi Akanuma; Myeongrae Han; Yuka Murayama; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Pharm Res       Date:  2022-02-02       Impact factor: 4.200

7.  Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey.

Authors:  Iftekhar Kalsekar; Jan-Samuel Wagner; Marco DiBonaventura; Jay Bates; Robert Forbes; Tony Hebden
Journal:  Health Qual Life Outcomes       Date:  2012-07-17       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.